FibroGen (FGEN) Begins LELANTOS-2, a Second Phase 3 Clinical Study of Pamrevlumab for Treatment of DMD
Go back to FibroGen (FGEN) Begins LELANTOS-2, a Second Phase 3 Clinical Study of Pamrevlumab for Treatment of DMD| (NASDAQ: FGEN) | Delayed: 1.06 -0.01 (0.93%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.07 | 52 Week High | $31.90 | |||
| Open | $1.06 | 52 Week Low | $14.38 | |||
| Day High | $1.10 | P/E | N/A | |||
| Day Low | $1.04 | EPS | $0.00 | |||
| Volume | 111,580 | |||||
